Correction to “Mitogen-Activated Protein Kinase Inhibition Augments the T Cell Response Against HOXB7-Expressing Tumor Through Human Leukocyte Antigen Upregulation”

IF 4.5 2区医学 Q1 ONCOLOGY

Cancer Science Pub Date : 2025-05-06 DOI:10.1111/cas.70094

{"title":"Correction to “Mitogen-Activated Protein Kinase Inhibition Augments the T Cell Response Against HOXB7-Expressing Tumor Through Human Leukocyte Antigen Upregulation”","authors":"","doi":"10.1111/cas.70094","DOIUrl":null,"url":null,"abstract":"Komatsuda H, Wakisaka R, Kono M, et al. Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation. Cancer Sci. 2023;114:399–409. doi: 10.1111/cas.15619In the above article, there were errors in the following texts:From Section 3.2:Based on computer-based algorithms, HOXB78-25 (PLLLKLLKSVGAQKD) was selected as a potential candidate for eliciting antigen-specific HTL responses.The correct text should be as follows:Based on computer-based algorithms, HOXB78-25 (NTLFSKYPASSSVFATGA) was selected as a potential candidate for eliciting antigen-specific HTL responses.From Section 4:As HOXB718-26 (SSVFAPGAF) might bind to HLA-A*26:01 in in silico analysis, the elongation of HOXB78-25 to HOXB78-26 would improve the antigenicity of the peptide by inducing both HTLs and CTLs.The correct text should be as follows:As HOXB718-26 (SSVFATGAF) might bind to HLA-A*26:01 in in silico analysis, the elongation of HOXB78-25 to HOXB78-26 would improve the antigenicity of the peptide by inducing both HTLs and CTLs.We apologize for these errors.","PeriodicalId":9580,"journal":{"name":"Cancer Science","volume":"116 7","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2025-05-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cas.70094","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cas.70094","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Komatsuda H, Wakisaka R, Kono M, et al. Mitogen-activated protein kinase inhibition augments the T cell response against HOXB7-expressing tumor through human leukocyte antigen upregulation. Cancer Sci. 2023;114:399–409. doi: 10.1111/cas.15619

In the above article, there were errors in the following texts:

From Section 3.2:

Based on computer-based algorithms, HOXB7_8-25 (PLLLKLLKSVGAQKD) was selected as a potential candidate for eliciting antigen-specific HTL responses.

The correct text should be as follows:

Based on computer-based algorithms, HOXB7_8-25 (NTLFSKYPASSSVFATGA) was selected as a potential candidate for eliciting antigen-specific HTL responses.

From Section 4:

As HOXB7_18-26 (SSVFAPGAF) might bind to HLA-A*26:01 in in silico analysis, the elongation of HOXB7_8-25 to HOXB7_8-26 would improve the antigenicity of the peptide by inducing both HTLs and CTLs.

The correct text should be as follows:

As HOXB7_18-26 (SSVFATGAF) might bind to HLA-A*26:01 in in silico analysis, the elongation of HOXB7_8-25 to HOXB7_8-26 would improve the antigenicity of the peptide by inducing both HTLs and CTLs.

We apologize for these errors.

查看原文本刊更多论文

更正“丝裂原活化蛋白激酶抑制通过上调人白细胞抗原增强T细胞对表达hoxb7的肿瘤的反应”。

小松田H， Wakisaka R, Kono M，等。丝裂原活化蛋白激酶抑制通过上调人白细胞抗原增强T细胞对表达hoxb7的肿瘤的应答。中国生物医学工程学报（英文版）；2009;31(4):379 - 379。doi: 10.1111 / ca。15619在上述文章中，以下文本存在错误：来自第3.2节：基于计算机算法，选择HOXB78-25 （PLLLKLLKSVGAQKD）作为引发抗原特异性html应答的潜在候选者。基于计算机算法，选择HOXB78-25 （NTLFSKYPASSSVFATGA）作为引发抗原特异性html应答的潜在候选基因。由于HOXB718-26 （SSVFAPGAF）在硅分析中可能与HLA-A*26:01结合，因此HOXB78-25延伸到HOXB78-26可以通过诱导HTLs和ctl来提高肽的抗原性。正确的文本应该是：HOXB718-26 （SSVFATGAF）在硅质分析中可能与HLA-A*26:01结合，HOXB78-25延伸到HOXB78-26可以通过诱导HTLs和ctl来提高肽的抗原性。我们为这些错误道歉。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Science 医学-肿瘤学

自引率

3.50%

发文量

406

审稿时长

2 months

期刊介绍： Cancer Science (formerly Japanese Journal of Cancer Research) is a monthly publication of the Japanese Cancer Association. First published in 1907, the Journal continues to publish original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational and clinical cancer research. The Journal also accepts reports and case reports. Cancer Science aims to present highly significant and timely findings that have a significant clinical impact on oncologists or that may alter the disease concept of a tumor. The Journal will not publish case reports that describe a rare tumor or condition without new findings to be added to previous reports; combination of different tumors without new suggestive findings for oncological research; remarkable effect of already known treatments without suggestive data to explain the exceptional result. Review articles may also be published.